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Improving outcome after stroke: overcoming the translational
roadblock
Abstract
Stroke poses a massive burden of disease, yet we have few effective therapies. The paucity of
therapeutic options stands contrary to intensive research efforts. The failure of these past investments
demands a thorough re-examination of the pathophysiology of ischaemic brain injury. Several critical
areas hold the key to overcoming the translational roadblock: (1) vascular occlusion: current
recanalization strategies have limited effectiveness and may have serious side effects; (2) complexity of
stroke pathobiology: therapy must acknowledge the 'Janus-faced' nature of many stroke targets and must
identify endogenous neuroprotective and repair mechanisms; (3) inflammation and
brain-immune-system interaction: inflammation contributes to lesion expansion, but is also instrumental
in lesion containment and repair; stroke outcome is modulated by the interaction of the injured brain
with the immune system; (4) regeneration: the potential of the brain for reorganization, plasticity and
repair after injury is much greater than previously thought; (5) confounding factors, long-term outcome
and predictive modelling. These 5 areas are linked on all levels and therefore need to be tackled by an
integrative approach and innovative therapeutic strategies.
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repair; stroke outcome is modulated by the interaction of the 
injured brain with the immune system; (4) regeneration: the 
potential of the brain for reorganization, plasticity and repair 
after injury is much greater than previously thought; (5) con-
founding factors, long-term outcome and predictive model-
ling. These 5 areas are linked on all levels and therefore need 
to be tackled by an integrative approach and innovative 
therapeutic strategies.  Copyright © 2008 S. Karger AG, Basel 
 Is There a Future for Neuroprotection after Stroke? 
 Stroke poses a massive clinical, social and economic 
burden, yet we have very limited effective therapies. This 
inadequacy exists in spite of intensive research efforts 
and numerous failed clinical trials  [1] . The latest of
these, SAINT-II (Stroke Acute Ischaemic NXY Treat-
ment, testing the free radical spin trap agent NXY-059) 
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 Abstract 
 Stroke poses a massive burden of disease, yet we have few 
effective therapies. The paucity of therapeutic options 
stands contrary to intensive research efforts. The failure of 
these past investments demands a thorough re-examina-
tion of the pathophysiology of ischaemic brain injury. Sev-
eral critical areas hold the key to overcoming the translation-
al roadblock: (1) vascular occlusion: current recanalization 
strategies have limited effectiveness and may have serious 
side effects; (2) complexity of stroke pathobiology: therapy 
must acknowledge the ‘Janus-faced’ nature of many stroke 
targets and must identify endogenous neuroprotective and 
repair mechanisms; (3) inflammation and brain-immune-
system interaction: inflammation contributes to lesion ex-
pansion, but is also instrumental in lesion containment and 
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and DIAS-2 (Desmoteplase in Acute Ischaemic Stroke, 
testing the vampire bat plasminogen activator des-
moteplase), showed no efficacy even though there were 
extensive and convincing preclinical as well as phase IIb 
or early phase III data available  [2–7] . Therefore, in our 
opinion, the apparent failure of bench-to-bedside trans-
lation demands a reappraisal of the pathophysiology of 
ischaemic brain injury and subsequent repair processes. 
In this article, we propose potential new approaches to 
what remains a common and devastating disorder.
 Once a brain vessel has become occluded, a complex 
series of cellular and molecular events is rapidly set in 
motion. Cells depolarize and swell, excitatory amino ac-
ids and K + ions are released while intracellular Ca 2+ levels 
soar (‘excitotoxicity’,  fig. 1 ). It is this acute phase of focal 
cerebral ischaemia which was at the focus of numerous 
failed neuroprotection trials of the recent decades  [8–10] . 
However, after a rather dramatic phase of early damage 
the lesion may indeed continue to grow many hours and 
even days after the onset of ischaemia. Targeting the un-
derlying mechanisms may widen the time window for 
treatment. We have learnt that the brain mounts a potent, 
but only partially successful, defensive response against 
many of the deleterious secondary mechanisms ( fig. 1 ). 
‘Learning from nature’ by inducing such mechanisms or 
treating with the effector molecules may result in more 
effective treatment with fewer unwanted side effects. In 
addition, only recently have we learnt that the brain, al-
beit with incomplete success, attempts to repair itself  [11, 
12] . 
 The pathomechanisms of cerebral ischaemia and their 
interactions are exceedingly complex, and many act as a 
‘double-edged sword’, with both beneficial and deleteri-
ous actions ( fig. 1 ): the dual effects of reperfusion were 
mentioned above. Glutamate is a major player in excito-
toxicity  [13] ; however, it is essential for normal brain 
function and a key driving force of reorganization and 
synaptogenesis after injury  [14] . Nitric oxide (NO) de-
rived from endothelia may increase blood flow while 
neuronal and inducible NO synthase (NOS) may contrib-
ute to the formation of peroxynitrite and hydroxyl anions 
 [15, 16] . Inflammation exacerbates ischaemic injury, but 
also provides the necessary environment for regeneration 
and repair  [17] . Formation of a glial scar may contain the 
lesion and impede its progression, but at the same time 
produces a barrier for axonal sprouting  [18] . Apoptosis 
contributes to lesion growth, but also inhibits inflamma-
tion  [19] . Stroke induces immunodepression but at the 
price of an increased susceptibility to infection  [20] . This 
list of ‘Janus-faced’ mechanisms could be further extend-
ed. Unfortunately, there appears to be no simple good-
versus-bad dichotomy: time, cellular context and stimu-
lus intensity are important in determining whether the 
same molecule, signalling pathway or cell will partake in 
destruction or repair. 
 Improving the Safety of Reperfusion 
 Thrombolysis is the only means of reversing vessel ob-
struction and inducing reperfusion. Yet, thrombolysis 
carries risks, particularly of intracerebral haemorrhage 
 [21] . At present, recombinant tissue plasminogen acti-
vator (rtPA) is the only approved agent. A promising 
 approach is ultrasound-mediated thrombolysis (sono-
thrombolysis) alone or in combination with rtPA and so-
nothrombolysis using targeted abciximab immuno-bub-
bles  [22] .
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 Fig. 1. Simplified pathobiology of stroke-
induced damage, endogenous repair and 
regeneration. 
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 Paradoxically, the benefit of intravenous tPA may be 
limited by neurotoxity  [23–25] . Excitotoxic effects of rtPA 
occur through the binding to the cell surface receptor 
low-density-lipoprotein-receptor-related protein  [26] or 
annexin II, or by cleaving the NR1 subunit of the N-
methyl- D -aspartate receptor which leads to increased 
calcium influx and subsequent neuronal death  [27, 28] . 
Hence, tPA is a molecule with two faces, one which is 
clearly beneficial based on its thrombolytic activity and a 
second which could be deleterious based on its neuro-
toxic effect ( fig. 2 ). 
 Reperfusion: Challenges and Opportunities 
 – Research is needed to increase the efficacy and appli-
cability of thrombolysis, for example by extending the 
time window, use of new thrombolytic compounds, 
sonothrombolysis and combination treatment. 
 – Studies should be undertaken to explore alternative 
strategies avoiding possible negative actions of rtPA in 
the brain. The idea is to prevent the deleterious neuro-
toxic effects of tPA without affecting its benefical 
thrombolytic activity. 
 – Combination treatment should be explored combin-
ing thrombolysis and neuroprotective, anti-inflam-
matory agents, or brain cooling. 
 The Neurovascular Unit in Stroke: Trigger and 
Target  
 An important site of inflammation after stroke and 
thus target for therapy is the neurovascular unit, which 
consists of a complex cellular system including circulat-
ing blood elements, endothelial cells, pericytes, perivas-
cular antigen-presenting cells, astrocytic end-feet and 
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 Fig. 2. Beneficial thrombolytic and delete-
rious neurotoxic effects of tPA. 
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neurones ( fig. 3 )  [29] . While the endothelial cells form the 
blood-brain barrier (BBB) proper, the interaction with 
the adjacent cells and the extracellular matrix is a prereq-
uisite for barrier function. 
 Maintenance of the BBB relies on a continuous, yet 
poorly characterized cross-talk between the cells of the 
neurovascular unit. Polarized astrocytes covering central 
nervous system (CNS) microvessels by their end-feet con-
tribute to the proper BBB function. Compromising their 
normal distribution on the astrocyte surface will lead to 
oedema, a hallmark of ischaemic brain damage ( fig. 3 ). 
Cellular infiltration and oedema formation during auto-
immune CNS inflammation lead to cleavage of extracel-
lular matrix proteins like   -dystroglycan, a transmem-
brane receptor in the astroglial end-foot  [30] , suggesting 
that polarization of astrocytes within the neurovascular 
unit is central to maintenance of the BBB ( fig. 3 ). 
 It is well established that recruitment of circulating 
immune cells across the BBB after stroke causes BBB 
breakdown and reperfusion injury. In order to under-
stand which leucocyte subpopulations confer beneficial 
rather than detrimental effects, it is mandatory to under-
stand first the multi-step recruitment cascade of leuco-
cyte subpopulations across the BBB  [31] . To date, these 
processes have been investigated mostly during auto-im-
mune CNS inflammation  [32] . In this context, recruit-
ment of pathogenic T lymphocytes across the BBB is 
unique, relying mainly on   4 -integrins  [33] and occurs 
through the endothelial cells of the BBB. In contrast to 
preclinical evidence, stroke trials inhibiting leucocyte re-
cruitment across the BBB by blocking ICAM-1/LFA-1 in-
teraction have been disappointing, supporting the notion 
of insufficient knowledge on the sequence of events in-
volved in leucocyte recruitment across the BBB during 
and after stroke. After ischaemia, the integrity of the neu-
rovascular unit is compromised by mechanisms that in-
clude cellular interactions with the activated endotheli-
um (see below), oxidative stress, up-regulation of prote-
ases such as matrix metalloproteinases and plasminogen 
activators (including tPA) leading to matrix degeneration 
and leakage of the BBB. The neurovascular unit is a logi-
cal target for stroke therapy; at the same time it provides 
important mechanistic links between tPA, matrix metal-
loproteinases, inflammation, oedema formation and 
haemorrhage after stroke.
 The Neurovascular Unit: Challenges and 
Opportunities 
 – Understanding the molecular and cellular mecha-
nisms of BBB maintenance is a prerequisite to under-
stand the BBB response to focal cerebral ischaemia.  
 – Elucidating the sequence of molecular traffic signals 
involved in the multi-step recruitment of different leu-
cocyte populations across the BBB during stoke is es-
sential in order to target the pathogenic leucocytes 
while maintaining the recruitment of repair cells.  
 Stroke and Inflammation: Beyond a Simple
‘Good-versus-Bad’ Dichotomy 
 Inflammation is the basic mechanism by which tissues 
of multicellular organisms respond to injury. The in-
flammatory response in stroke involves not only leuco-
cytes, endothelial and glial cells but also neurones. At the 
molecular level, inflammation involves a complex cas-
cade of mediators. On the basis of current knowledge we 
propose the following mediators or processes to qualify 
as key components of the inflammatory reaction ( fig. 4 ). 
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 Fig. 3. The neurovascular unit. BBB endothelial cells (red) main-
tain homeostasis in the CNS (green) by forming a barrier against 
the changing milieu of the bloodstream. TJ = Tight junctions; 
APC = antigen-presenting cell. 
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 (1) Activated microglia/macrophages are character-
ized by their ability to migrate, differentiate, phagocytose 
and secrete a wide variety of molecules involved in in-
flammation  [34, 35] . In fact, microglia/blood-derived 
monocytic cells play a key role in the development of 
ischaemic lesions  [36] . 
 (2) Postischaemic inflammation unfolds and exerts 
its influences through a complex network of cytokines. 
Among other cytokines IL-1, IL-6, TNF and TWEAK 
have been implicated in stroke  [37, 38] . IL-1 appears to 
mediate injury at least during the acute phase, and the 
endogenous IL-1 receptor antagonist is potently neuro-
protective in diverse animal models  [37] . A recent phase 
II trial of IL-1 receptor antagonist versus placebo in 
acute stroke showed marked reductions in systemic in-
flammation (which is associated with poor outcome), no 
adverse effects and an indication of potential benefit 
 [38] .
 (3) NO produced by different NOS isoforms plays an 
important role following stroke. Brain ischaemia acti-
vates constitutively expressed neuronal NOS along with 
inducible NOS in leucocytes and macrophages leading to 
concentrations of NO that are toxic and contribute to sec-
ondary late-phase damage partly via formation of per-
oxynitrite, induction of DNA damage and activation of 
poly(ADP-ribose) polymerase  [15] . In contrast, NO gen-
erated by endothelial NOS is crucial for maintaining ce-
rebral blood flow and reducing infarct volume  [16] . 
 (4) Neuroinflammation in stroke causes BBB break-
down and neuronal damage, but at the same time confers 
neuroprotection. In order to manipulate this process, it is 
mandatory to understand the molecular events involved 
in BBB breakdown and the multi-step recruitment cas-
cade of leucocyte subpopulations across the highly spe-
cialized endothelium of the BBB (see above). 
 (5) Inflammation in cerebral ischaemia relies on the 
regulation of gene expression. Signal transduction path-
ways include oestrogen receptor, AP-1 and NF-  B  [39] . 
Binding to response elements in the promoter region of 
multiple genes they are master switches of the inflamma-
tory response. Thus, transcription factor signalling may 
provide defined molecular targets to interfere with di-
verse mechanisms of ischaemic brain damage  [40] .
 Inflammation after Stroke: Challenges and 
Opportunities 
 – We need to know how different cellular and molecular 
components interact to contribute to inflammatory 
responses in the CNS and impact on cerebrovascular 
disease.  
 – There is a need for benchmarking of accepted anti-in-
flammatory strategies in stroke. Is there a therapeutic 
principle with outstanding efficacy? 
 – Inflammation interacts with several other processes 
in stroke pathophysiology. Therefore, it is essential to 
use a broad definition of efficacy incorporating sev-
eral clinically relevant parameters beyond infarct vol-
ume.  
 Brain-Immune-System Interactions after Stroke 
 Stroke affects the normally well-balanced interplay of 
the two supersystems – the nervous and the immune sys-
tem  [20] . Reciprocally, the course and outcome of stroke 
are strongly affected by the immune status of the stroke 
victim at the time of stroke. Brain-immune-system inter-
actions are highly relevant for functional outcome after 
stroke. Stroke induces immunodepression and increases 
the susceptibility to infection. However, immunodepres-
sion after stroke may also have beneficial effects, for ex-
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 Fig. 4. Five key players of the inflammatory response in stroke 
have been identified, but their interrelation is unclear. Do they act 
in series or in parallel? Is there a target with outstanding efficacy? 
Do they modulate brain oedema, functional outcome, infarct vol-
ume and immune depression in a differential manner? 
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ample by suppressing immune-mediated responses dur-
ing injury-induced exposure of CNS-specific antigens 
 [41] . In the normal brain, co-stimulatory molecules are 
expressed only at low levels but become up-regulated upon 
brain damage such as stroke. In addition, systemic infec-
tion induces the up-regulation of co-stimulatory as well as 
major histocompatibility complex class I and II molecules 
in the periphery and the brain, thus sensitizing T and B 
cells to brain antigens. As noted above, stroke induces the 
production of pro-inflammatory cytokines. As a result of 
systemic inflammation, additional cytokines are pro-
duced outside and within the brain, which mediate as-
pects of sickness behaviour and lead to an exaggerated 
pro-inflammatory phenotype. Taken together, interac-
tions between the brain and adaptive as well as innate im-
munity are highly relevant for tissue damage, regenera-
tion as well as systemic infection after stroke, and present 
a target for protecting the brain, fostering its regeneration 
and preventing systemic complications ( fig. 5 ).
 Infection and Immunity in Stroke: Challenges and 
Opportunities 
 – Infections are the most important complications after 
stroke. Understanding the susceptibility of stroke pa-
tients to infections may result in their prevention and 
improved outcomes. 
 – Systemic inflammation and infections modulate the 
susceptibility to stroke and alter its pathobiology. Un-
derstanding the consequences of systemic inflamma-
tion for stroke will lead to novel strategies for the pre-
vention and treatment of stroke. 
 Inducing Endogenous Neuroprotection –
Learning from Nature?  
 Tissue damage and functional impairment after cere-
bral ischaemia are the result of the interaction of endog-
enous protective mechanisms and those events that ulti-
mately lead to cell death ( fig. 1 ). Recently, endogenous 
protective mechanisms have entered the centre stage in 
stroke research, and ‘ischaemic preconditioning’ (or 
‘ischaemic tolerance’) is widely used to study such endog-
enous neuroprotection  [42] . Practically any stimulus ca-
pable of causing damage, when applied close to the thresh-
old of damage, but below it, can protect the brain against 
subsequent ischaemia. Recent studies found evidence for 
ischaemic preconditioning/tolerance in the human brain 
 [43, 44] , which can guide investigators to targets for acute 
therapy.
 Several promising endogenous brain protectants have 
been identified so far, among them erythropoietin, IL-1 
receptor antagonist and granulocyte colony-stimulating 
factor, all of which are in clinical testing at present. In ad-
dition, there is evidence that many of the endogenous 
brain protectants also have regenerative activity, for ex-
ample by inducing neuro-, angio- and arteriogenesis (see 
below). 
 Endogenous Neuroprotection in Stroke:
Challenges and Opportunities 
 – We propose that research on endogenous brain pro-
tection can guide investigators to targets for acute 
therapy against the consequences of brain ischaemia. 
 – Future research needs to identify brain-specific vari-
ants of these molecules, and elucidate the signalling 
pathways. 
 – Clinical trials need to test the most promising candi-
dates. Trials in high-risk collectives (e.g. heart or brain 
surgery) should investigate the possibility to induce 
ischaemia tolerance (e.g. by inducing hypoxia-induc-
ing factor 1) to preventively protect the brain against 
cerebrovascular complications. 
 – The mechanisms of mild hypothermic neuroprotec-
tion (in combination with the above) need to be eluci-
dated. 
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 Fig. 5. Mechanisms of stroke-induced immunosuppression. 
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 Regeneration and Repair: The Next Frontier  
 Neurogenesis: Epiphenomenon or Causative for 
Regeneration? 
 In the adult brain, neural stem/progenitor cells are lo-
calized along the lateral ventricle in the subventricular 
zone. Stroke triggers increased cell proliferation in the 
subventricular zone in rodents  [45] . Newly formed neu-
roblasts migrate into the damaged striatum  [46] , where 
they mature and express markers characteristic of striatal 
medium spiny neurones  [47, 48] . It is now important to 
establish whether neurogenesis can contribute to func-
tional recovery after stroke, a causal relationship has yet 
to be established. It is also important to determine if neu-
rogenesis from endogenous stem/progenitor cells occurs 
after stroke in humans  [49] . Postischaemic inflammation 
(see above) may be detrimental for the survival of the 
newly born neurones  [50, 51] , but the interplay between 
neurogenesis and inflammation in CNS pathologies re-
mains controversial  [52] . Clarification of the role of in-
flammatory processes for the different steps of stroke-in-
duced neurogenesis might explain the lack of efficacy of 
this potential self-repair mechanism and lead to the iden-
tification of novel therapeutic targets.
 Promoting Regeneration via the Formation of New 
Vessels?  
 Brain ischaemia promotes the formation of new ves-
sels with altered morphology and microvascular struc-
ture  [53] . Stem and progenitor cells from the bone mar-
row, in particular so-called endothelial progenitor cells, 
may promote vascular repair, neovascularization and im-
prove endothelial function  [54, 55] . Only recently has it 
become apparent that poststroke angiogenesis can in-
deed promote regeneration  [56, 57] . How the formation 
of new vessels improves recovery even at time points 
when neuronal and axonal cell death is already complet-
ed remains to be elucidated. 
 Plasticity and Synaptogenesis 
 It is well documented that housing rodents in an en-
riched environment even after damage has fully matured 
can enhance plasticity and improve functional recovery 
by stimulating axonal outgrowth, and that constraint-in-
duced movement therapy stimulates recovery of motor 
functions after stroke in humans. The recovery process 
following ischaemia is a complex and highly dynamic 
process  [58] . In a later phase dendritic arborization, axo-
nal growth and cell genesis enhance formation of new 
neural networks. Details of how these processes develop 
over time and how they are regulated are largely un-
known and open new venues for the pharmacology of 
stroke. Only recently has a number of pharmacological 
strategies been established in preclinical models by which 
poststroke re-organization of the adult brain can be en-
hanced, e.g. by inactivation of the Nogo-A/NgR signal-
ling system  [59] , the tophic factors erythropoietin and 
granulocyte colony-stimulating factor  [60, 61] , or poten-
tially activators of the basal forebrain cholinergic system, 
such as cholinesterase inhibitors  [62] .
 Neurorepair after Stroke: Challenges and 
Opportunities 
 – Long-term studies and complex end points including 
a number of functional tests along with hallmarks of 
regeneration may be better suited to determine stroke 
outcome. 
 – Research is needed to demonstrate whether neurogen-
esis causally contributes to functional recovery. Do 
newly generated neurones make synaptic contacts? 
Does ablation of newly generated neurones have an 
impact on outcome? 
 – Does new vessel formation contribute to improved 
long-term outcome? Is this via enhanced neurogene-
sis? 
 – We propose to explore in more detail the role of in-
flammation in neurogenesis, angiogenesis and repair 
after stroke. 
 – We propose to explore the factors regulating axonal 
outgrowth and spine remodelling, in order to develop 
novel therapeutic strategies that stimulate functional 
recovery.  
 – We propose to explore factors that are involved in the 
enhancing recovery of function by excercise and en-
riched environment. 
 Modelling of Stroke: Crossing the ‘Valley of Death’  
 More than 150 clinical trials (for an overview, see 
www.strokecenter.org) have aimed at establishing an ef-
fective brain-protective therapy after stroke, but with 
very few exceptions most have failed. So how do we ex-
plain the failure of bench-to-bedside translation in 
stroke, and how can we improve on it? Two key concepts 
which successfully found their way into clinical practice 
are: the concept of the ischaemic penumbra  [63–65] and 
thrombolysis in acute ischaemic stroke were both devel-
oped in animal models of cerebral ischaemia  [66, 67] . 
The Stroke Therapy Academic Industry Roundtable 
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(STAIR)  [1] has published ‘recommendations for stan-
dards regarding preclinical neuroprotective and restor-
ative drug development’. With the failure of SAINT-II, 
which fulfilled many of these recommendations, includ-
ing testing in subhuman primates, are the STAIR recom-
mendations a failure? A critical analysis of the preclini-
cal NXY-059 data, however, and of a number of short-
comings argues that SAINT-II does not refute the utility 
of the STAIR criteria  [3, 4] . A number of recent system-
atic reviews of experimental stroke research  [68–70] have 
clearly demonstrated that practically all treatments that 
were tested clinically were not evaluated preclinically in 
comparable populations. Also, the vast majority of clin-
ical trials used treatment windows to the very edge of 
efficacy in rodent models, i.e. 5–6 h after stroke onset. In 
contrast, almost all of the few studies that have compared 
the effect of atherosclerosis, diabetes, age or gender have 
found that these confounders drastically affect not only 
the pathobiology of stroke, but also the potential benefit 
of treatment. In addition, O’Collins et al.  [10] have re-
cently systematically evaluated experimental studies on 
1,026 putative neuroprotectants and concluded that the 
drugs taken forward to clinical trial have not been dis-
tinguished by superior efficacy. It is therefore clearly pre-
mature to pronounce the end of the neuroprotection era 
or to denounce the relevance of preclinical testing in 
models faithful to human pathology. There is an urgent 
need for academic investigators and the pharmaceutical 
industry to detect promising treatments and the possi-
bility of failure at the earliest stage as possible. We pro-
pose that an academic, public and industry multi-disci-
plinary collaboration focuses on the following mea-
sures.
 Modelling of Stroke: Challenges and Opportunities 
 – Use of clinically relevant end-points (functional out-
come, behaviour) at clinically relevant end-points 
(weeks or months instead of hours or days after stroke) 
in preclinical research. 
 – Modelling of confounding diseases, in particular hy-
pertension, arteriosclerosis, diabetes. 
 – Modelling of the most important risk factor for stroke: 
age. 
 – Investigating gender-specific effects. 
 – Development of models for lacunar stroke and white-
matter injury.  
 – Developing preclinical surrogate markers of effective-
ness using surrogate markers already established in 
humans (bed-to-bench translation). 
 – Development and validation of brain imaging ap-
proaches (structural, functional, molecular) applica-
ble preclinically as well as clinically to demonstrate 
CNS effects and predict effectiveness. 
 – Observation of quality standards, establishment of a 
trial register and funding of replication studies in pre-
clinical stroke research. 
 Clinical Stroke Trial Design 
 Clearly, the apparent failure of neuroprotection in hu-
man stroke cannot be blamed on deficiencies of experi-
mental research alone. While this review was focused on 
the problems and future challenges of translational stroke 
research, a few comments on clinical stroke trials appear 
warranted. 
 Clinical trials continue to reflect the hope that one or 
more single variables could reflect the disease process 
and show the benefits of therapy. Examples include the 
early complex clinical scales like the Toronto, Mathew, 
NIH (modified or not), Canadian, Frithz-Werner, Orgo-
gozo and Scandinavian. Recently the Rankin scale (also 
modified or not) has become more popular, seems to 
many simpler than the Barthel index and is more readily 
applied by a wide range of investigators. Of interest, the 
Rankin scale has proved more useful interventionally 
than in drug trials for ischaemic stroke. The most recent 
disappointment has been with NXY-059  [3] . Hopes that 
imaging methods might provide useful surrogates have 
also been blunted by the just-completed phase III des-
moteplase study DIAS-2  [7] . 
 That stroke is not a unitary disease state is obvious to 
all, but to date there has been a great reluctance to follow 
the infectious disease model. Here, symptoms and signs 
can reflect a wide variety of different, identifiable causes, 
many having unique treatment sensitivities, each of 
which must be discovered and pursued for the gratifying 
therapeutic outcome. As proposed in the current review, 
why not apply such an approach to stroke? 
 Admittedly, sponsors of clinical trials find it tiresome 
to spend huge resources with the likelihood their agent 
will be approved for but a narrow subset of cases. They 
understandably keep hoping for a global favourable re-
sult, only to have the subset of responders lost, buried or 
arguably not discoverable in the broad array of cases test-
ed in a trial. Reeling from successive failures, the combat-
ants may be becoming exhausted and could abandon the 
field entirely. Many have already. If too many do so, we 
may have a long road ahead in shaping new test methods 
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to demonstrate the utility of treatments already on hand 
which have yet to have made the translational step from 
animal model to human. 
 Conclusion 
 The past two decades have witnessed an enormous ex-
pansion in our understanding of events that determine 
the fate of brain cells following vessel occlusion. Cell 
death following brain ischaemia is mediated by a com-
plex interplay of a number of pathophysiologically dis-
tinct mechanisms. Both, blood vessels and parenchyma 
have been implicated in this interplay, and their complex 
interactions define the fate of compromised tissues and 
cells. Improvement of reperfusion, inhibition of second-
ary damage as well as induction of endogenous protec-
tion and repair deserve increased efforts to overcome the 
‘translational roadblock’ that appears to exist in the 
stroke field. Importantly, new strategies will have to wid-
en the time window for therapeutic interventions and 
may lead to the regeneration of lost function after stroke. 
Focussing on a limited number of key mechanisms, we 
will be able to establish an orderly sequence of events, to 
investigate the causal relation of individual mechanisms 
and to identify novel and promising therapeutic targets. 
To achieve this, however, we will need to observe the 
complexity and heterogeneity of stroke pathobiology and 
the important impact of age and co-morbidity. Certainly, 
there will be no single agent or strategy, no ‘one size fits 
all’ approach for effective stroke treatment. Given the 
close link and interrelation of the different damage mech-
anisms, it is essential not (only) to use infarct size to as-
sess outcome but to consider also other clinically relevant 
parameters in the preclinical phase such as peripheral 
immune state, brain water content and long-term func-
tional outcome. Moreover, biomarkers (e.g. measured in 
blood) and novel imaging approaches may serve as sur-
rogate parameters and help to identify on an individual 
basis those patients suited for a particular therapy. Hence, 
despite the complexity and drawbacks, there is reason for 
optimism for a better translation of discoveries from 
bench to bedside. 
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